162 related articles for article (PubMed ID: 9144979)
1. Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy.
O'Marcaigh AS; Betcher DL
J Pediatr Oncol Nurs; 1997 Apr; 14(2):96-8. PubMed ID: 9144979
[No Abstract] [Full Text] [Related]
2. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
Gershanovich ML
Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530
[No Abstract] [Full Text] [Related]
3. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
4. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
5. [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].
Sauer H
Strahlenther Onkol; 1997 Jan; 173(1):51-2. PubMed ID: 9082586
[No Abstract] [Full Text] [Related]
6. Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
Hellmann K
J Clin Oncol; 1996 Feb; 14(2):332-3. PubMed ID: 8636740
[No Abstract] [Full Text] [Related]
7. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
8. [Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
Semiglazov VF
Vopr Onkol; 1997; 43(6):569-74. PubMed ID: 9479353
[No Abstract] [Full Text] [Related]
9. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
Lipshultz SE
J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739
[No Abstract] [Full Text] [Related]
10. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum RH
Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
[No Abstract] [Full Text] [Related]
11. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
13. Drug may protect children's hearts from chemotherapy.
McBride D
ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
[No Abstract] [Full Text] [Related]
14. [Cardiotoxicity of conservative treatment of solid tumors].
Sivak LA; Askol'skiĭ AV; Lial'kin SA; Klimanov MIu; Maĭdanevich NN; Kasap NV
Lik Sprava; 2011; (3-4):51-9. PubMed ID: 22416364
[TBL] [Abstract][Full Text] [Related]
15. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
16. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
17. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
[TBL] [Abstract][Full Text] [Related]
18. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Kwok JC; Richardson DR
Redox Rep; 2000; 5(6):317-24. PubMed ID: 11140743
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
[TBL] [Abstract][Full Text] [Related]
20. Dexrazoxane for protection against cardiotoxic effects of anthracyclines.
Sehested M; Holm B; Jensen PB
J Clin Oncol; 1996 Oct; 14(10):2884. PubMed ID: 8874349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
